Antipurinergic therapy corrects the autism-like features in the Fragile X (Fmr1 knockout) mouse model

Abstract

The data show that antipurinergic therapy improves the multisystem, ASD-like features of both the environmental MIA, and the genetic Fragile X models. These abnormalities appeared to be traceable to mitochondria and regulated by purinergic signaling.